secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2025-07-23T23:59:59+00:00
Accession:  0001214659-25-010830
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro FY2025 cash $3.9M, equity $3.9M; $5M financing completed ahead of schedule
--------------------------------------------------------------------------------

- Cash of $3.9M at April 30, 2025 vs $0.4M prior year; stockholder equity of $3.9M vs deficit $2.6M.
- Net cash from financing activities was $10.4M for FY2025.
- Completed $5M private placement in June 2025, months early; investor accelerated purchase of additional $4M preferred stock.
- Dosed first patient in May 2025 for AL001 'Lithium in Brain' Phase II studies at Mass General; topline results expected year-end 2025.
- ALZN002 immunotherapy trial delayed; actively seeking new CRO after prior CRO terminated in Feb 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465925010830/0001214659-25-010830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465925010830/i7232518k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-25-010830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer